Michael Amoroso, Precision BioSciences CEO
May 31, 2023 11:32 AM EDT
R&D
Cell/Gene Tx

Pre­ci­sion Bio­Sciences to meet with FDA af­ter tout­ing al­lo­gene­ic CAR-T win

Paul Schloesser

Associate Editor

Pre­ci­sion Bio­Sciences is now tout­ing new da­ta from a Phase I/II tri­al, say­ing that it has iden­ti­fied a dos­ing reg­i­men that it be­lieves will al­low …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times